Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 107815
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.107815
Correlation of radiotherapy, targeted therapy, and immunotherapy with hepatocellular carcinoma recurrence
Qian-Jia Liu, Jia-Cheng Zhang, Yue-Fan Wang, Ming-Hao Zou, Wen-Xuan Zhou, Yan Lu, Xiao-Chen Feng, Hui Liu
Qian-Jia Liu, Jia-Cheng Zhang, Yue-Fan Wang, Ming-Hao Zou, Wen-Xuan Zhou, Yan Lu, Xiao-Chen Feng, Hui Liu, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai 200082, China
Co-first authors: Qian-Jia Liu and Jia-Cheng Zhang.
Co-corresponding authors: Xiao-Chen Feng and Hui Liu.
Author contributions: Liu H and Feng XC contributed to the conception of this manuscript, the tables and the figure; Liu QJ and Zhang JC co-authored this review; Wang YF, Zou MG, Zhou WX, Lu Y provided suggestions and revised this review; Liu QJ and Zhang JC have made equal contributions to the drafting of the manuscript and the organization of the literature as co-first authors of this manuscript; Liu H and Feng XC have made equal contributions to the conception and revision of the manuscript and as co-corresponding authors; All authors read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. 82270634; and Third Affiliated Hospital of Naval Medical University, No. tf2024yzyy01.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Liu, PhD, Chief Doctor, Professor, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, No. 225 Changhai Road, Shanghai 200082, China. liuhuigg@hotmail.com
Received: April 1, 2025
Revised: April 30, 2025
Accepted: June 19, 2025
Published online: July 15, 2025
Processing time: 107 Days and 9.8 Hours
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is a prevalent cancer worldwide, ranking as the third leading cause of cancer-related deaths. Despite advancements in treatment modalities, a significant proportion of patients with HCC (50%-70%) experience tumor recurrence within 5 years of initial treatment. This review focuses on the roles of radiotherapy, targeted therapy, and immunotherapy in managing post-surgical HCC recurrence and their combined effects.